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Abstract
Background: Neuropilin-2 (Nrp2) is a receptor for vascular endothelial growth factor-C (VEGF-C),
which is a well-known lymphangiogenic factor and plays an important role in lymph node metastasis of
various human cancers, including breast cancer. Recently, Nrp2 was shown to play a role in cancer by
promoting tumor cell metastasis. CXC chemokine receptor 4 (CXCR4) also promotes tumor metastasis.
In the previous studies, we demonstrated that VEGF-C and cytoplasmic CXCR4 expressions were
correlated with poorer patient prognosis (BMC Cancer 2008,8:340; Breast Cancer Res Treat 2005,
91:125–132).
Methods: The relationship between Nrp2 expression and lymph node metastasis, VEGF-C expression,
CXCR4 expression, and other established clinicopathological variables (these data were cited in our
previous papers), including prognosis, was analyzed in human breast cancer. Effects of neutralizing anti-
Nrp2 antibody on CXCR4 expression and chemotaxis were assessed in MDA-MB-231 breast cancer cells.
Results: Nrp2 expression was observed in 53.1% (60 of 113) of the invasive breast carcinomas. Nrp2
expression was significantly correlated with lymph node metastasis, VEGF-C expression, and cytoplasmic
CXCR4 expression. Survival curves determined by the Kaplan-Meier method showed that Nrp2
expression was associated with reduced overall survival. In multivariate analysis, Nrp2 expression emerged
as a significant independent predictor for overall survival. Neutralizing anti-Nrp2 antibody blocks
cytoplasmic CXCR4 expression and CXCR4-induced migration in MDA-MB-231 cells.
Conclusion: Nrp2 expression was correlated with lymph node metastasis, VEGF-C expression, and
cytoplasmic CXCR4 expression. Nrp2 expression may serve as a significant prognostic factor for long-
term survival in breast cancer. Our data also showed a role for Nrp2 in regulating cytoplasmic CXCR4
expression in vitro.
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Background
Neuropilin-2 (Nrp2) is a transmembrane glycoprotein
that interacts with vascular endothelial growth factor
(VEGF). Nrp2 is involved in the regulation of many phys-
iological conditions, including angiogenesis [1]. Previous
reports have suggested a possibility that Nrp may function
independently of VEGF receptors to modulate endothelial
cell migration, which may lead to angiogenesis [2,3].
Nrp2 is also known to function as a receptor for VEGF-C
[4,5], which is a well-known lymphangiogenic factor and
plays an important role in lymph node metastasis of vari-
ous human cancers [6], including breast cancer [7].
Recently, Nrp2 was shown to play a role in cancer by pro-
moting migration of breast cancer cells, which correlates
with tumor cell metastasis [8,9]. However, the role of
Nrp2 in human breast cancer is largely unknown.
Metastasis is the major cause of death associated with
solid tumors [10]. Metastasis of cancer cells is a complex
process including invasion, hemangiogenesis, lymphang-
iogenesis, trafficking of cancer cells through blood or
lymph vessels, extravasations, organ-specific homing, and
growth. Recent evidence suggests that CXC chemokine
receptor 4 (CXCR4) plays a critical role in the homing of
cancer cells to specific metastatic sites [11]. The CXCR4
ligand, CXCL12, was found to be expressed in liver, bone
marrow, lung, and lymph nodes, and also shown to pro-
mote migration of cancer cells [12]. Previous reports dem-
onstrated that up-regulated CXCR4 expression in human
cancers, including breast cancer, was correlated with
lymph node metastasis and unfavorable prognosis, and
was regulated by nitric oxide [13-15].
In this study, we examined the relationship of Nrp2 to
lymph node metastasis, VEGF-C expression, and CXCR4
expression in human breast cancer tissues, and further
investigated the potential value or relevance of Nrp2 for
predicting disease outcome. We then showed that an anti-
body against Nrp2 reduces cytoplasmic CXCR4 expres-
sion and inhibited CXCL12-induced chemotaxis in MDA-
MB-231 breast cancer cells, which were previously shown
to express endogenous Nrp2 [8].
Methods
Patients and tumor samples
This study was approved by the review board of the
Wakayama Medical University Medical Ethics Committee
and informed consent was obtained from each of the
patients. Archival paraffin-embedded specimens of inva-
sive breast cancer from 113 patients, who were diagnosed
and treated between 1981 and 1992 at the Osaka Police
Hospital, Japan, were selected as described previously
[16]. None of these cases had a family history of breast
cancer or malignancy in first-degree relatives as deter-
mined by questioning at the time of admission for sur-
gery. The patients had received mastectomy with axillary
lymph node dissection. All women were apparently free
of distant metastasis. All cases received post-operative
adjuvant therapy consisting of combination chemother-
apy and hormone treatment. Immunostaining for estro-
gen receptor (ER), progesterone receptor (PgR), VEGF-C,
and CXCR4 had been already performed and the results
had been previously described [14,17]. Positivity was
defined as nuclear staining of 10% or more cancer cells
with a strong intensity for ER and PgR. VEGF-C immuno-
reactivity was defined as the cases in which at least 10% of
tumor cells were immunoreactive. The intensity, staining
percentage, and pattern of staining (nuclear and cytoplas-
mic) were assessed for CXCR4. The intensity was scored as
low, moderate, and strong compared with background
staining. The percentages of positive cells were estimated
by calculating the ratio of the positively stained invasive
tumor cells to the total invasive cells. Nuclear versus cyto-
plasmic location of expression was also noted in each
sample. The staining patterns of tumors for CXCR4 was
defined as high cytoplasmic expression (moderate and >
50%, or strong and > 30% cytoplasmic expression) or pre-
dominantly nuclear expression (at least 80% nuclear
expression). The size of the primary tumor was deter-
mined from the surgical specimen. Lymph node metasta-
sis was determined by counting the number of axillary
lymph nodes with histological evidence of metastatic
breast carcinoma. Histological typing and grading were
done according to the WHO classification [18] and the
Nottingham method (Bloom Richardson) [19]. Patient
and tumor characteristics are shown in Table 1. The
median age of the 113 patients at diagnosis was 51 years
(range, 24–87 years). Fifty-eight percent of the patients
were younger than 50 years (n = 65), and 52% (n = 59) of
the patients had lymph node metastasis at the time of sur-
gery. Twenty-six percent of the patients had distant organ
metastasis during the follow-up period (n = 29).
Immunohistochemistry
For immunostaining, 4-micrometer thick paraffin sec-
tions were de-paraffinized, placed in a solution of 97%
methanol and 3% hydrogen peroxide for 5 min, then
autoclaved for antigen retrieval. After washing in phos-
phate-buffered saline (PBS), the slides were treated for 20
min with Protein Block Serum-free (DAKO Cytomation,
Carpinteria, CA, USA). This was followed by an overnight
incubation at 4°C in a humidified chamber with a 1:20
diluted goat anti-human Nrp2 antibody (R & D Systems,
Inc, Minneapolis, MN, USA). After the overnight treat-
ment, Histofine SAB-PO (NICHIREI, Tokyo, Japan) was
used as the second antibody, according to the manufac-
turer's instructions. Color was developed using diami-
nobenzidine with 0.01% hydrogen peroxide, and
hematoxylin was used as a counterstain. For the negative
control, all reagents except for the primary antibody wereBMC Cancer 2009, 9:220 http://www.biomedcentral.com/1471-2407/9/220
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used. The immunohistochemical scoring was performed
blindedly by 3 pathologists (HY, RK, and YN), who had
no clinical knowledge of the patients. The immunos-
tained sections of two representative slides of each case
were examined by light-microscopy, and all tumor areas
were analyzed for Nrp2 positivity, which was defined as
the cases in which at least 10% of tumor cells were immu-
noreactive.
Cell culture
The MDA-MB-231 breast carcinoma cell line was pur-
chased from the American Type Culture Collection
(ATCC, Rockville, MD, USA). MDA-MB-231 cells were
maintained at 37°C in 95% air and 5% CO2, as monolay-
ers in tissue culture dishes containing DMEM medium
(Invitrogen, Tokyo, Japan) supplemented with 10% heat-
inactivated fetal calf serum (FCS) (HyClone, South Logan,
UT, USA). For the experiments, 6 cm tissue culture plates
(Corning Inc, Corning, NY, USA) were seeded with 5 ×
105 cells in 3 mL of medium + 10% FCS. Next day, media
was changed to FCS-free medium, and then neutralizing
anti-Nrp2 antibody (final concentration was 3 micro-
gram/mL) was added. This concentration of Nrp2 anti-
body had no effect on cell viability as measured by the
CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (Promega, Madison, WI, USA) (data not shown).
Determination of CXCR4 protein expression
For the determination of CXCR4 protein expression,
MDA-MB-231 cell lines were incubated for 12 hours with
or without neutralizing anti-Nrp2 antibody, and then har-
vested. Cell lysates were prepared using NE-PER™ Nuclear
and Cytoplasmic Extraction Reagents (Pierce, Rockford,
IL, USA) containing Halt™ Protease Inhibitor Cocktail
(Pierce). For Western blot analysis of CXCR4, 40 micro-
gram samples of nuclear extracts or cytoplasmic fractions
were separated by electrophoresis in 10–20% SDS poly-
acrylamide gels, and transferred to PVDF membranes by
electroblotting as described previously [16]. The mem-
brane was blocked with 5% skim milk in PBS for 1 h at
room temperature, incubated overnight with anti-human
CXCR4 rabbit antibody (Abcam Ltd., Cambridge, UK),
washed with PBS, and labeled with peroxidase-conjugated
anti-rabbit secondary antibody (Dako Cytomation, Den-
mark) for 1 h at room temperature. The signals were visu-
alized using the LumiGLO Reserve chemiluminescence
substrate kit (KPL, Inc, Gaithersburg, MD, USA) and
recorded by luminocapture (ATTO, Tokyo, Japan). Anti-
beta-2-microglobulin antibody (Dako Cytomation) was
used for the internal control of cytoplasmic extract. Anti-
transcription factor IID antibody (Upstate, Lake Placid,
NY, USA) was used for the internal control of nuclear
extract.
Table 1: The relationship between Neuropilin-2 expression and other parameters.
Neuropilin-2 p value
Factor Negative Positive
Age < 50 35 (54%) 30 (46%) 0.0911
51 18 (38%) 30 (62%)
Histology Ductal 47 (45%) 57 (55%) 0.4328
Lobular 3 (60%) 2 (40%)
Medullary 1 (100%) 0 (0%)
Mucinous 2 (67%) 1 (33%)
Tumor size pT1 19 (53%) 17 (47%) 0.4240
pT2–4 34 (44%) 43 (56%)
Lymph node metastasis Negative 31 (57%) 23 (43%) 0.0389
Positive 22 (37%) 37 (63%)
Estrogen receptor Negative 22 (49%) 23 (51%) 0.8476
Positive 31 (46%) 37 (54%)
Progesterone receptor Negative 24 (47%) 27 (53%) 1.0000
Positive 29 (47%) 33 (53%)
Histological grade I and II 34 (51%) 33 (49%) 0.3440
III 19 (41%) 27 (59%)
VEGF-C Negative 17 (85%) 3 (15%) < 0.001
Positive 36 (39%) 57 (61%)
CXCR4 (cytoplasmic) Negative 37 (65%) 20 (35%) < 0.001
Positive 16 (29%) 40 (71%)
CXCR4 (nuclei) Negative 42 (50%) 42 (50%) 0.2879
Positive 11 (38%) 18 (62%)
Distant metastasis Negative 41 (49%) 43 (51%) 0.5243
Positive 12 (41%) 17 (59%)BMC Cancer 2009, 9:220 http://www.biomedcentral.com/1471-2407/9/220
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Chemotaxis assay
Migration assay was performed in 24-well plates using
inserts with 8 micrometer pore size membranes (BD Bio-
sciences, Bedford, MA, USA). The surface of the mem-
branes was precoated with 50 microliter of fibronectin
(BD Biosciences) in PBS (25 microgram per mL) per filter,
allowed to dry at room temperature, and washed with
PBS. MDA-MB-231 cells were suspended at 1 × 106 cells/
mL in FCS-free medium and placed in the upper chambers
of the membrane. At the same time, the lower compart-
ment of the chamber was loaded with or without 400 ng/
mL of recombinant human CXCL12 (R&D Systems), and
the upper compartment of the chamber was placed with
or without neutralizing anti-Nrp2 antibody (final concen-
tration was 3 microgram/mL). After incubation for 24
hours, the chamber was removed, and cells that had
migrated to the bottom of the membrane were fixed,
stained in Cyto Quick Solution (Muto Pure Chemical,
Tokyo, Japan), and counted by light microscopy. All
assays were done in triplicate.
Statistical analysis
Fisher's exact test was used to examine the association of
various clinicopathological factors including Nrp2, VEGF-
C expression, and cytoplasmic or nuclear CXCR4 expres-
sion. Overall survival (OS) curves and disease-free sur-
vival (DFS) curves were obtained using the Kaplan-Meier
method and compared using the log-rank test. A multivar-
iate model using the Cox stepwise regression analysis was
used to evaluate the statistical strength of independent
association between covariates and DFS and/or OS. The
effects of neutralizing anti-Nrp2 antibody treatment were
analyzed by Student's t test. A p value less than 0.05 was
considered significant. A software package (JMP IN 5.1.1,
SAS Institute, Cary, NC, USA) was used for all statistical
testing and management of the database.
Results
Nrp2 expression in breast cancer tissue
In normal breast tissue (Figure 1A), Nrp2 staining was
observed in blood or lymph vessels, while there was no
staining in normal breast epithelium. In cancer tissue,
staining of the Nrp2 protein was identified not only in the
vascular endothelial cells, but also in the cytoplasm of
cancer cells. In some cases, almost all invasive cells were
immunopositive for Nrp2 (Figure 1B). Nrp2 expression
was identified in both marginal and central areas of the
tumor. According to the criteria for Nrp2 immunostaining
evaluation, Nrp2 protein was positive in 53.1% (60 of
113) of the invasive breast carcinomas.
Nrp2 expression is correlated with lymph node metastasis, 
VEGF-C expression, and cytoplasmic CXCR4 expression
As we described previously [17], the expression of VEGF-
C protein was observed as diffuse cytoplasmic staining in
breast cancer cells. VEGF-C expression was positive in
82% (93 of 113) of the breast cancer patients. Nrp2
expression tended to be co-localized or adjacent to VEGF-
C expression (data not shown). In the previous study on
immunostaining of CXCR4, cytoplasmic staining had
been prominent than nuclear staining [14]. Cytoplasmic
staining with a nuclear component had been observed in
20% (23 of 113) of those tumors, predominantly nuclear
staining in 5% (6 of 113), predominantly cytoplasmic
staining in 29% (33 of 113), and no staining in 45% (51
of 113). In the cases with both Nrp2 and CXCR4 positiv-
ity, co-localized expression of these two proteins was
observed on sequential sections of the tumors (Figures
1C–D). As shown in Table 1, Nrp2 expression was corre-
lated with lymph node metastasis (p = 0.0389), VEGF-C
expression (p < 0.001), and cytoplasmic CXCR4 expres-
sion (p < 0.001).
Nrp2 expression is correlated with patients' survival
Survival analysis was performed on 113 patients and the
following variables were examined: Nrp2 expression,
tumor size, lymph node metastasis, hormonal status, his-
tological grade, VEGF-C expression, and cytoplasmic or
nuclear CXCR4. As shown in previous reports [7,14], uni-
variate survival analysis showed that tumor size, lymph
node metastasis, ER status, VEGF-C expression, and cyto-
plasmic CXCR4 expression had significant prognostic
value for DFS. Lymph node metastasis, VEGF-C expres-
sion, cytoplasmic CXCR4 expression, and also Nrp2
Neuropilin-2 (Nrp2) expression in normal breast and breast  carcinoma tissue Figure 1
Neuropilin-2 (Nrp2) expression in normal breast and 
breast carcinoma tissue. (A) Nrp2 staining was observed 
in blood or lymph vessels. There was no staining in normal 
breast epithelium. (×100). (B) In cancer tissue, staining of the 
Nrp2 protein was identified not only in the vascular endothe-
lial cells, but also in the cytoplasm of cancer cells. Almost all 
invasive cells were immunopositive for Nrp2. (×200). (C-D) 
Co-localized expression of Nrp2 (C) and CXCR4 (D) using 
serial sections of breast carcinoma tissue. (×100).BMC Cancer 2009, 9:220 http://www.biomedcentral.com/1471-2407/9/220
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expression as shown in this study (p = 0.0268) had signif-
icant prognostic value for OS (Figure 2). Multivariate Cox
regression analysis of all covariates focusing on DFS iden-
tified histological grade (p = 0.0099) as a significant inde-
pendent prognostic factor, while both histological grade
and Nrp2 expression were identified as independent prog-
nostic factors for OS (histological grade, p = 0.0093; Nrp2
expression, p = 0.0453).
Anti-Nrp2 blocks CXCR4 expression and CXCR4-induced 
migration
As we had previously shown, endogenous cytoplasmic or
nuclear CXCR4 expression was observed in the MDA-MB-
231 cell line [14]. In this study, treatment of the cells with
anti-Nrp2 antibody significantly inhibited cytoplasmic
CXCR4 protein expression, although nuclear CXCR4 pro-
tein expression was unchanged in the treated cells (Figure
3). As shown in Figure 4, MDA-MB-231 cells showed sig-
nificant chemotactic response to CXCL12. Furthermore,
the chemotactic responses of MDA-MB-231 cells were sig-
nificantly blocked by neutralizing anti-Nrp2 antibody.
Discussion
The present study, to our knowledge, is the first one to
demonstrate the clinicopathological significance of Nrp2
expression in human breast cancer. In normal breast epi-
thelium, Nrp2 expression was not observed. In normal
and cancer tissue, Nrp2 expression was identified in blood
or lymph vessels. In addition to cytoplasmic VEGF-C and
cytoplasmic CXCR4 expression, that had been already
reported, Nrp2 expression was correlated with lymph
node status and was positive in 53.1% of cases.
Previously, we reported that lymph node metastasis is cor-
related with cytoplasmic CXCR4 expression [14]. Given
that Nrp2 expression was significantly correlated with
cytoplasmic CXCR4 expression, we considered the possi-
Association of Nrp2 expression with prognosis of patients  with breast cancer (Kaplan-Meier method and log-rank test) Figure 2
Association of Nrp2 expression with prognosis of 
patients with breast cancer (Kaplan-Meier method 
and log-rank test). Nrp2 expression was significantly cor-
related to death (p = 0.0268).
Effect of neutralizing anti-Nrp2 antibody on CXCR4 expres- sion Figure 3
Effect of neutralizing anti-Nrp2 antibody on CXCR4 
expression. MDA-MB-231 cells were treated with neutral-
izing anti-Nrp2 antibody and prepared for Western blot anal-
ysis. Treatment of the cells with anti-Nrp2 antibody 
significantly inhibited cytoplasmic CXCR4 protein expres-
sion. Nuclear CXCR4 protein expression was unchanged in 
this cell line.
Effect of neutralizing anti-Nrp2 antibody on CXCL12- induced chemotaxisis Figure 4
Effect of neutralizing anti-Nrp2 antibody on 
CXCL12-induced chemotaxisis. The chemotactic 
responses of MDA-MB-231 cells were significantly blocked 
by neutralizing anti-Nrp2 antibody. *Indicates significant dif-
ference (p < 0.05) from control and/or anti-Nrp2 antibody-
treated cells.BMC Cancer 2009, 9:220 http://www.biomedcentral.com/1471-2407/9/220
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bility that Nrp2 expression with VEGF-C stimulation is
involved in the expression of cytoplasmic CXCR4. In the
present study, treatment of the MDA-MB-231 breast can-
cer cell line, which express Nrp2, endogenous VEGF-C,
and cytoplasmic or nuclear CXCR4 [8,14,16], with anti-
Nrp2 antibody significantly inhibited cytoplasmic CXCR4
protein expression. Furthermore, the chemotactic
responses of MDA-MB-231 cells were significantly
blocked by neutralizing anti-Nrp2 antibody. In these cells,
cytoplasmic CXCR4 expression was unchanged after
administration of recombinant human VEGF-C protein
(wild type or Cys156Ser) (data not shown). Endogenous
VEGF-C expression may be sufficient for endogenous
CXCR4 expression, and Nrp2 with endogenous VEGF-C
stimulation may regulate cytoplasmic CXCR4. Our data
support the previous report that downregulation of Nrp2
in cancer cells can lead to fewer metastasis [20]. In addi-
tion, it is known that expression of CXCR4 in MDA-MB-
231 cells is dependent on VEGF signaling [21]. Since the
Nrp2 antibody blocked CXCR4 expression at 12 h after
administration, the Nrp2 antibody may be affecting
CXCR4 expression through the inhibition of VEGF signal-
ing rather than inhibiting CXCR4 directly.
In this study, survival curves determined by the Kaplan-
Meier method and univariate analysis demonstrated that
Nrp2 expression was negatively associated with OS. Fur-
thermore, multivariate analysis using the Cox stepwise
regression analysis demonstrated that Nrp2 expression
was still correlated with poor OS after consideration of
other prognostic factors. Therefore, Nrp2 expression
appears to be a reliable prognostic biomarker. Although
we reported previously that cytoplasmic CXCR4 expres-
sion may become a useful prognostic indicator for OS,
cytoplasmic CXCR4 expression was not identified as an
independent prognostic factor for OS in this study (p =
0.0735). Considering that Nrp2 was correlated with
poorer prognosis despite no correlation with distant
metastasis, it may be necessary to increase the number of
cases in the future study.
Conclusion
Nrp2 expression is significantly correlated with VEGF-C
expression, cytoplasmic CXCR4 expression, and lymph
node metastasis in breast cancer. Nrp2 expression may
serve as a significant prognostic factor for long-term sur-
vival in breast cancer. Nrp2 also regulates cytoplasmic
expression of functional CXCR4 expression in vitro.
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